"If," (and only if) Treasury refuses, why can't YMI do a workaround?
Example: YMI gets 100% of the NIMO rights for North America, or Worldwide, from Cuba. YMI, thru Oncoscience AG, pays Cuba a royalty on European Tesmilifene sales. Or, Shin Poo pays a royalty to Cuba from Korean sales. You get the idea. As long as there are no direct US product sales paying a royalty stream to Cuba...no problems.
John/IO/one of you guys, think about asking this of management in person next month.